Human Papillomavirus and Cervical Cancer Epidemiology

Human papillomavirus (HPV) infection, particularly with persistent high-risk genotypes, underpins the development of cervical cancer. Transmission typically occurs through intimate skin-to-skin contact, with most infections resolving spontaneously; however, a subset of viral types can evade immune clearance and induce precancerous cellular changes. The global burden of cervical cancer remains substantial, with age-standardised incidence and mortality rates highest in regions with limited access to organised screening and vaccination. In high-income countries, regular cytology or HPV-based screening has driven down incidence, whereas low- and middle-income countries continue to shoulder the majority of new cases and deaths. Vaccination against key HPV types, alongside expanded screening strategies—including self-sampling and molecular triage—promises to reduce disease burden. Epidemiological models project that comprehensive vaccination and primary HPV testing could accelerate declines in mortality, aligning with public health goals for disease elimination. Socioeconomic disparities, HIV co-infection and rural–urban divides further shape regional trends, underscoring the need for tailored interventions and resource allocation.

Research from Nature Portfolio

Recent studies have employed large-scale modelling to assess screening strategies across diverse settings. One analysis evaluated multiple primary screening scenarios in low- and lower-middle-income countries, demonstrating that HPV-based screening every five years offers superior effectiveness and cost-effectiveness compared with cytology or visual inspection approaches. Triage options such as HPV genotyping or cytology reduced overtreatment without compromising mortality gains, informing global screening guidelines. In parallel, an integrative genomic study of hundreds of cervical tumours revealed novel mutational signatures, identified key driver genes and immune checkpoints, and characterised patterns of viral integration. This work delineated distinct molecular subgroups—including HPV-negative, endometrial-like tumours—and highlighted potential therapeutic targets, bridging epidemiology with precision oncology and supporting more personalised approaches to management.

Human Papillomavirus and Cervical Cancer Epidemiology publication trend

The graph below shows the total number of articles in human papillomavirus and cervical cancer epidemiology across all publications each year (not limited to Nature Index journals).

Technical terms

Human papillomavirus (HPV): A group of DNA viruses, some of which infect the anogenital tract and can cause benign or malignant lesions.

Age-standardised incidence rate: A summary measure of the number of new cases per 100 000 population, adjusted to a standard age distribution to allow comparison across regions.

Cytology: Examination of cells from the cervix, typically via a Pap smear, to detect precancerous changes.

Visual inspection with acetic acid (VIA): A low-cost screening technique in which the cervix is examined after application of acetic acid to highlight abnormal epithelium.

Genomic integration: The process by which HPV DNA becomes incorporated into the host cell’s genome, often driving oncogenic transformation.

APOBEC mutagenesis: A pattern of DNA editing by the APOBEC family of enzymes, associated with characteristic mutations in viral and host genomes.

References

1. Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population. Nature Medicine (2023).
2. Integrated genomic and molecular characterization of cervical cancer. Nature (2017).
3. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health (2019).
4. Estimates of the global burden of cervical cancer associated with HIV. The Lancet Global Health (2020).
5. National age-specific mortality trends for cervical and breast cancers in urban–rural areas of China from 2009 to 2021: a population-based analysis. Military Medical Research (2024).